Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Elevation Oncology (ELEV) announced it will present preclinical data for EO-1022, its novel HER3 antibody drug conjugate (ADC), at the AACR Annual Meeting 2025 in Chicago. EO-1022 combines seribantumab, a human IgG2 anti-HER3 monoclonal antibody, with monomethyl auristatin E (MMAE) payload using Synaffix's site-specific conjugation technology.
The company is developing EO-1022 for treating HER3-expressing solid tumors, specifically targeting breast cancer and non-small cell lung cancer. The presentation will showcase the first preclinical data for this therapeutic candidate, which features a drug-to-antibody ratio of 4. Elevation Oncology plans to file an Investigational New Drug (IND) application in 2026.
Elevation Oncology (ELEV) ha annunciato che presenterà dati preclinici per EO-1022, il suo nuovo coniugato anticorpale anti-HER3 (ADC), al AACR Annual Meeting 2025 a Chicago. EO-1022 combina seribantumab, un anticorpo monoclonale umano IgG2 anti-HER3, con il payload monometil auristatina E (MMAE) utilizzando la tecnologia di coniugazione specifica per il sito di Synaffix.
L'azienda sta sviluppando EO-1022 per il trattamento di tumori solidi che esprimono HER3, mirando specificamente al cancro al seno e al cancro polmonare non a piccole cellule. La presentazione mostrerà i primi dati preclinici per questo candidato terapeutico, che presenta un rapporto farmaco-anticorpo di 4. Elevation Oncology prevede di presentare una domanda di Nuovo Farmaco Sperimentale (IND) nel 2026.
Elevation Oncology (ELEV) anunció que presentará datos preclínicos para EO-1022, su nuevo conjugado de anticuerpo anti-HER3 (ADC), en la AACR Annual Meeting 2025 en Chicago. EO-1022 combina seribantumab, un anticuerpo monoclonal humano IgG2 anti-HER3, con el payload monometil auristatina E (MMAE) utilizando la tecnología de conjugación específica de sitio de Synaffix.
La empresa está desarrollando EO-1022 para tratar tumores sólidos que expresan HER3, enfocándose específicamente en el cáncer de mama y el cáncer de pulmón no microcítico. La presentación mostrará los primeros datos preclínicos para este candidato terapéutico, que presenta una relación fármaco-anticuerpo de 4. Elevation Oncology planea presentar una solicitud de Nuevo Medicamento en Investigación (IND) en 2026.
Elevation Oncology (ELEV)는 EO-1022, 자사의 새로운 HER3 항체 약물 접합체(ADC)의 전임상 데이터를 AACR 연례 회의 2025에서 시카고에서 발표할 것이라고 발표했습니다. EO-1022는 인체 IgG2 항-HER3 단클론 항체인 세리반투맙과 모노메틸 아우리스타틴 E(MMAE) 페이로드를 Synaffix의 사이트 특이적 접합 기술을 사용하여 결합합니다.
회사는 HER3을 발현하는 고형 종양을 치료하기 위해 EO-1022를 개발하고 있으며, 특히 유방암과 비소세포 폐암을 목표로 하고 있습니다. 이번 발표에서는 이 치료 후보의 첫 전임상 데이터가 공개되며, 약물-항체 비율은 4입니다. Elevation Oncology는 2026년에 임상시험 신약(IND) 신청서를 제출할 계획입니다.
Elevation Oncology (ELEV) a annoncé qu'elle présentera des données précliniques pour EO-1022, son nouvel anticorps conjugué anti-HER3 (ADC), lors de la AACR Annual Meeting 2025 à Chicago. EO-1022 combine le sériantumab, un anticorps monoclonal humain IgG2 anti-HER3, avec le chargeur monométhyl auristatine E (MMAE) en utilisant la technologie de conjugaison spécifique au site de Synaffix.
L'entreprise développe EO-1022 pour traiter des tumeurs solides exprimant HER3, ciblant spécifiquement le cancer du sein et le cancer du poumon non à petites cellules. La présentation mettra en avant les premières données précliniques pour ce candidat thérapeutique, qui présente un rapport médicament-anticorps de 4. Elevation Oncology prévoit de déposer une demande de nouveau médicament expérimental (IND) en 2026.
Elevation Oncology (ELEV) gab bekannt, dass es präklinische Daten zu EO-1022, seinem neuartigen HER3-Antikörper-Arzneimittel-Konjugat (ADC), auf dem AACR Annual Meeting 2025 in Chicago präsentieren wird. EO-1022 kombiniert Seribantumab, einen menschlichen IgG2-Anti-HER3-Monoklonalen Antikörper, mit dem Monomethyl-Auristatin E (MMAE) Payload unter Verwendung der standortspezifischen Konjugationstechnologie von Synaffix.
Das Unternehmen entwickelt EO-1022 zur Behandlung von HER3-exprimierenden soliden Tumoren, insbesondere mit Fokus auf Brustkrebs und nicht-kleinzelliges Lungenkarzinom. Die Präsentation wird die ersten präklinischen Daten für diesen therapeutischen Kandidaten zeigen, der ein Verhältnis von Arzneimittel zu Antikörper von 4 aufweist. Elevation Oncology plant, im Jahr 2026 einen Antrag auf einen Untersuchungsneuen Arzneimittel (IND) zu stellen.
- First preclinical data presentation for novel HER3 ADC therapeutic candidate
- Utilizes clinically validated MMAE payload with unique HER3-targeting approach
- Potential to treat patients refractory to other HER3-targeting agents
- Early-stage development - still in preclinical phase
- IND filing not planned until 2026
- No clinical efficacy data available yet
-- Abstract accepted for late-breaking poster presentation –
-- EO-1022 is a potentially differentiated HER3 ADC being developed for the treatment of solid tumors, including breast and non-small cell lung cancers --
-- On-track to file an Investigational New Drug (IND) application in 2026 –
EO-1022 is an antibody drug conjugate (ADC) containing seribantumab, a fully human IgG2 anti-HER3 monoclonal antibody (mAb), which is site-specifically conjugated at glycan to the monomethyl auristatin E (MMAE) payload with a drug-to-antibody ratio (DAR) of 4. Elevation Oncology designed EO-1022, leveraging the advanced site-specific conjugation technology platform licensed from Synaffix B.V. Elevation Oncology is developing EO-1022 for the treatment of solid tumors that express HER3, including breast cancer and non-small cell lung cancer, and expects to file an IND application in 2026.
"We are eager to share the first preclinical data for EO-1022 at the AACR Annual Meeting," said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology. "With EO-1022, we are combining the most advanced site-specific conjugation technology platform with the clinically validated MMAE payload, which is widely used across ADC programs but has yet to be introduced into a HER3-targeting ADC in the clinic. We believe this unique combination will enable us to provide a new treatment option to patients with HER3-expressing solid tumors, including those who are refractory to other HER3-targeting agents in development. We look forward to advancing EO-1022 into clinical development next year."
Details of the poster presentation at AACR 2025 are as follows:
Title: Preclinical discovery and characterization of EO-1022, a site-specific glycan-conjugated anti-HER3 vc-MMAE ADC for treating solid tumors
- Abstract Presentation Number: LB004
- Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 1
- Session Date and Time: Sunday, April 27, from 2 p.m. to 5 p.m. CT (3 p.m. to 6 p.m. ET)
- Location: Poster Section 50
The late-breaking abstract will become available on the AACR website beginning at 12:00 noon CT (1:00 p.m. ET) on April 25, 2025, and published in an online-only supplement to Cancer Research.
About EO-1022
Elevation Oncology is developing EO-1022, a potentially differentiated HER3 ADC for the treatment of HER3-expressing solid tumors, including breast cancer and non-small cell lung cancer. EO-1022 consists of seribantumab, a fully human IgG2 anti-HER3 antibody, site-specifically conjugated at glycan to the MMAE payload with a DAR of 4. It leverages seribantumab's desirable internalization properties and advanced site-specific ADC technology which makes possible the use of the potent cytotoxic MMAE payload. Elevation Oncology expects to file an IND application in 2026.
About Elevation Oncology, Inc.
Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are leveraging our ADC expertise to advance EO-1022, a HER3 ADC for the treatment of patients with HER3-expressing solid tumors. EO-1022 is currently progressing through preclinical development, with an investigational new drug (IND) application expected in 2026. For more information, visit www.ElevationOncology.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated clinical and preclinical development activities, expected timing of announcements of preclinical results, potential benefits of product candidates, potential market opportunities for product candidates and the ability of product candidates to treat their targeted indications. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "might," "plan," "possible," "potential," "will," "would," and other words and terms of similar meaning. Although Elevation Oncology believes that the expectations reflected in such forward-looking statements are reasonable, Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval are inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Elevation Oncology's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Elevation Oncology's ability to advance its product candidates, the timing and results of preclinical studies and clinical trials, approvals and commercialization of product candidates, the receipt and timing of potential regulatory designations, Elevation Oncology's ability to fund development activities and achieve development goals, Elevation Oncology's ability to protect intellectual property, Elevation Oncology's ability to establish and maintain collaborations with third parties, and other risks and uncertainties described under the heading "Risk Factors" in documents Elevation Oncology files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Elevation Oncology undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Elevation Oncology Investor and Media Contact
Gracie Tong
Senior Director, Investor Relations and Corporate Communications
gtong@elevationoncology.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-present-preclinical-data-for-eo-1022-at-the-american-association-for-cancer-research-aacr-annual-meeting-2025-302407842.html
SOURCE Elevation Oncology
FAQ
What is the target indication for Elevation Oncology's EO-1022 (ELEV)?
When will Elevation Oncology (ELEV) file the IND application for EO-1022?
What technology platform is used in Elevation Oncology's EO-1022 development?
Where and when will Elevation Oncology present EO-1022 preclinical data?
